Name | Number of supported studies | Average coverage | |
---|---|---|---|
oligodendrocyte | 15 studies | 47% ± 15% | |
oligodendrocyte precursor cell | 15 studies | 57% ± 19% | |
astrocyte | 15 studies | 58% ± 20% | |
endothelial cell | 13 studies | 26% ± 8% | |
adipocyte | 10 studies | 59% ± 18% | |
fibroblast | 9 studies | 37% ± 18% | |
smooth muscle cell | 9 studies | 23% ± 9% | |
epithelial cell | 8 studies | 36% ± 22% | |
basal cell | 7 studies | 41% ± 24% | |
cardiac muscle cell | 6 studies | 67% ± 22% | |
mesothelial cell | 6 studies | 31% ± 10% | |
type I pneumocyte | 6 studies | 38% ± 14% | |
type II pneumocyte | 6 studies | 57% ± 17% | |
GABAergic neuron | 5 studies | 30% ± 6% | |
pericyte | 5 studies | 27% ± 10% | |
ciliated cell | 5 studies | 28% ± 11% | |
podocyte | 4 studies | 61% ± 27% | |
plasma cell | 4 studies | 28% ± 13% | |
retinal pigment epithelial cell | 4 studies | 45% ± 18% | |
retinal cone cell | 4 studies | 48% ± 19% | |
retinal rod cell | 4 studies | 55% ± 18% | |
hepatocyte | 4 studies | 61% ± 19% | |
glutamatergic neuron | 4 studies | 25% ± 7% | |
club cell | 4 studies | 38% ± 10% | |
hepatic stellate cell | 3 studies | 44% ± 18% | |
differentiation-committed oligodendrocyte precursor | 3 studies | 54% ± 9% | |
glial cell | 3 studies | 27% ± 9% | |
granule cell | 3 studies | 21% ± 3% | |
endocardial cell | 3 studies | 38% ± 9% | |
muscle cell | 3 studies | 30% ± 13% | |
abnormal cell | 3 studies | 40% ± 24% | |
ependymal cell | 3 studies | 56% ± 18% | |
transit amplifying cell | 3 studies | 44% ± 29% | |
kidney distal convoluted tubule epithelial cell | 3 studies | 64% ± 33% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 99% | 4459.45 | 2623 / 2642 | 99% | 37.46 | 701 / 705 |
kidney | 100% | 4514.21 | 89 / 89 | 98% | 21.37 | 879 / 901 |
prostate | 100% | 7819.64 | 245 / 245 | 97% | 18.92 | 489 / 502 |
liver | 100% | 7911.56 | 226 / 226 | 97% | 22.08 | 394 / 406 |
thymus | 100% | 6536.76 | 653 / 653 | 96% | 20.32 | 583 / 605 |
skin | 99% | 7570.11 | 1787 / 1809 | 97% | 31.27 | 459 / 472 |
esophagus | 100% | 9316.89 | 1443 / 1445 | 96% | 15.54 | 175 / 183 |
intestine | 99% | 6532.74 | 960 / 966 | 95% | 16.42 | 502 / 527 |
bladder | 100% | 12752.71 | 21 / 21 | 94% | 15.81 | 473 / 504 |
breast | 100% | 6323.24 | 459 / 459 | 91% | 12.84 | 1014 / 1118 |
uterus | 100% | 9470.39 | 170 / 170 | 88% | 14.03 | 406 / 459 |
stomach | 92% | 3835.69 | 332 / 359 | 95% | 15.23 | 272 / 286 |
pancreas | 95% | 2815.02 | 312 / 328 | 92% | 9.86 | 163 / 178 |
ovary | 98% | 3618.05 | 177 / 180 | 87% | 10.28 | 374 / 430 |
lung | 81% | 2500.92 | 470 / 578 | 90% | 10.56 | 1035 / 1155 |
adipose | 100% | 6538.48 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 17676.08 | 1335 / 1335 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 35.69 | 80 / 80 |
ureter | 0% | 0 | 0 / 0 | 100% | 6.90 | 1 / 1 |
muscle | 99% | 6984.88 | 796 / 803 | 0% | 0 | 0 / 0 |
heart | 95% | 9706.94 | 819 / 861 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 91% | 12.78 | 41 / 45 |
adrenal gland | 67% | 1333.46 | 172 / 258 | 20% | 1.55 | 45 / 230 |
lymph node | 0% | 0 | 0 / 0 | 59% | 12.41 | 17 / 29 |
spleen | 27% | 502.76 | 65 / 241 | 0% | 0 | 0 / 0 |
peripheral blood | 0% | 7.78 | 4 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0035024 | Biological process | negative regulation of Rho protein signal transduction |
GO_0030837 | Biological process | negative regulation of actin filament polymerization |
GO_2000393 | Biological process | negative regulation of lamellipodium morphogenesis |
GO_0008283 | Biological process | cell population proliferation |
GO_2000114 | Biological process | regulation of establishment of cell polarity |
GO_0090263 | Biological process | positive regulation of canonical Wnt signaling pathway |
GO_0046627 | Biological process | negative regulation of insulin receptor signaling pathway |
GO_0030036 | Biological process | actin cytoskeleton organization |
GO_0010977 | Biological process | negative regulation of neuron projection development |
GO_0035023 | Biological process | regulation of Rho protein signal transduction |
GO_0090521 | Biological process | podocyte cell migration |
GO_1900025 | Biological process | negative regulation of substrate adhesion-dependent cell spreading |
GO_0030336 | Biological process | negative regulation of cell migration |
GO_1900028 | Biological process | negative regulation of ruffle assembly |
GO_0030177 | Biological process | positive regulation of Wnt signaling pathway |
GO_0090303 | Biological process | positive regulation of wound healing |
GO_0032587 | Cellular component | ruffle membrane |
GO_0005856 | Cellular component | cytoskeleton |
GO_0005886 | Cellular component | plasma membrane |
GO_0005634 | Cellular component | nucleus |
GO_0005737 | Cellular component | cytoplasm |
GO_0008013 | Molecular function | beta-catenin binding |
GO_0005515 | Molecular function | protein binding |
Gene name | KANK1 |
Protein name | KN motif and ankyrin repeat domain-containing protein 1 (Ankyrin repeat domain-containing protein 15) (Kidney ankyrin repeat-containing protein) KN motif and ankyrin repeat domains 1 KANK1 protein |
Synonyms | KIAA0172 ANKRD15 KANK |
Description | FUNCTION: Involved in the control of cytoskeleton formation by regulating actin polymerization. Inhibits actin fiber formation and cell migration . Inhibits RhoA activity; the function involves phosphorylation through PI3K/Akt signaling and may depend on the competitive interaction with 14-3-3 adapter proteins to sequester them from active complexes . Inhibits the formation of lamellipodia but not of filopodia; the function may depend on the competitive interaction with BAIAP2 to block its association with activated RAC1 . Inhibits fibronectin-mediated cell spreading; the function is partially mediated by BAIAP2. Inhibits neurite outgrowth. Involved in the establishment and persistence of cell polarity during directed cell movement in wound healing. In the nucleus, is involved in beta-catenin-dependent activation of transcription. Potential tumor suppressor for renal cell carcinoma. Regulates Rac signaling pathways . . |
Accessions | ENST00000689214.1 ENST00000685947.1 [Q14678-1] ENST00000687796.1 [Q14678-2] ENST00000688039.1 A0A8I5KTS9 Q6PIB3 ENST00000685590.1 ENST00000382286.3 ENST00000692757.1 A0A8I5KNW9 A0A8I5KUI5 ENST00000693088.1 ENST00000382293.7 [Q14678-2] ENST00000619269.5 A0A8J9BYE6 A0A8I5KT40 ENST00000382297.7 [Q14678-1] ENST00000687662.1 ENST00000690372.1 [Q14678-2] ENST00000693021.1 ENST00000690348.1 ENST00000693143.1 ENST00000691319.1 ENST00000382289.7 Q8WUM7 ENST00000674102.1 [Q14678-1] A0A8I5KVK4 ENST00000685380.1 ENST00000691645.1 A0A8I5KP85 Q5W0W2 ENST00000382303.5 [Q14678-1] ENST00000689926.1 A0A8I5KRP2 ENST00000689779.1 [Q14678-1] A0A8I5KZ49 A0A8I5KUD8 A0A8I5KSV2 Q14678 A0A8I5KUM3 Q5W0W3 A0A8I5QKT2 A0A8I5KXH8 ENST00000692345.1 |